Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis

American Journal of Pathology

Volumn 157, Issue 3, 2000, Pages 905-918

  Singhrao, Sim K ^a   Neal, James W ^a   Rushmere, Neil K ^a   Morgan, B Paul ^a   Gasque, Philippe ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; MEMBRANE PROTEIN;

ARTICLE; ASTROCYTE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOLYSIS; FETUS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; NERVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM;

EID: 0034495294     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64604-4     Document Type: Article

References (65)

1. The properdin system and immunity. I. Demonstration of a new serum protein, properdin and its role in immune phenomena
2. Initiation of complement activation
3. Experimente ueber die Bakterienfeind-lichen. Einfluesse des tierischen korpers
4. Molecular organization and function of the complement system
5. Uber die bakterientodtende Wirkung des zellfreien Blutserums
6. Complement regulation
7. Regulation in the activation pathways - Membrane RCA proteins
8. Regulation in the terminal pathway - Membrane regulators of the terminal pathway
9. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study
10. Complement activation in amyloid plaques in Alzheimer's dementia
11. Activation of the classical complement pathway in brain tissue of Alzheimer patients
12. Immunocytochemical localization of the terminal complement complex in multiple sclerosis
13. A4 acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease
14. Complement proteins and complement inhibitors in Alzheimer's disease
15. Expression of the complement membrane attack complex and its inhibitor in Pick's disease brain
16. Role of complement in the aetiology of Pick's disease?
17. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease
18. Complement activation in the central nervous system following blood-brain barrier damage in man
19. Complement activation by β-amyloid in Alzheimer disease
20. Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis
21. Expression of complement components of the alternative pathway by glioma cell lines
22. Expression of the complement classical pathway by human glioma in culture
23. Complement expression in human brain: Biosynthesis of terminal pathway components and regulators in glial cell lines
24. Complement biosynthesis in the central nervous system
25. Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation
26. The expression of CD59 in normal human nervous tissue
27. Human oligodendrocytes are not sensitive to complement
28. The expression of complement regulatory proteins by adult human oligodendrocytes
29. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement
30. Normal rat serum cytotoxicity, against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies
31. Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in the absence of antibody
32. Killing of the rat glial cells by complement: Deficiency of the rat analogue of CD59 is the cause of oligodendrocyte susceptibility to lysis
33. Complement activation on human neuroblastoma cell lines in vitro: Route of activation and expression of functional complement regulatory proteins
34. CD59 expression and complement susceptibility of human neuronal cell line (Nterra2)
35. Complement-mediated neurotoxicity is regulated be homologous restriction
36. Effect of peroxynitrite on the mitochondrial respiratory chain: Differential susceptibility of neurons and astrocytes in primary culture
37. Expression of the receptor for complement C5a (CD88) is upregulated on reactive astrocytes, microglia, and endothelial cells in inflamed human central nervous system
38. Identification of an astrocyte cell population from human brain that expresses perforin, a cytotoxic protein implicated in immune defense
39. Activated mouse astrocytes and T cells express similar CD44 variants. Role of CD44 in astrocyte/T cell binding
40. CD44 expression in human astrocytes and oligodendrocytes in culture
41. Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP)
42. CD59, an Ly-6 like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells
43. Sulfated glycoprotein-2 is increased in rat hippocampus following entorhinal cortex lesioning
44. Distribution of clusterin in Alzheimer brain tissue
45. Activation of the complement cascade and increase of clusterin in the brain following a cortical contusion in the adult rat
46. The blood-brain barrier and the inflammatory response
47. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes
48. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: Analysis in multiple sclerosis and bacterial meningitis
49. Primary cultures of murine astrocyte produce C3 and factor B, two components of the alternative pathway of complement activation
50. Induction of C3 expression in astrocytes is regurated by cytokines and New Castle disease virus
51. Complement mRNA in the mammalian brain. Responses to Alzheimer's disease and experimental brain lesioning
52. The C3-activator system: An alternative pathway of complement activation
53. Control of the amplification convertase of complement by the plasma protein β1H
54. A new function of the activated third component of complement: Binding to C5, an essential step for C5 activation
55. Induced expression of neuronal membrane attack complex and cell death by Alzheimer's β-amyloid peptide
56. Complement activation by isolated myelin: Activation of the classical pathway in the absence of myelin-specific antibodies
57. Antibody-independent complement activation and myelin via the classical complement pathway
58. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP)
59. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis
60. Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation
61. Soluble recombinant complement receptor I inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis
62. xglycosylated complement inhibitory protein
63. Up-regulated expression of decay-accelerating factor (CD55) confers increased complement resistance to sprouting neural cells
64. Differential expression of individual complement regulators in the brain and choroid plexus